Bora plants its flag in the US with $210M acquisition of generics manufacturer Upsher-Smith

Preview

来源: FiercePharma

On Bora Pharmaceuticals' $210 million acquisition of Upsher-Smith, Bora CEO Booby Sheng said that the "competitiveness" of the Minnesota generics manufacturer "is a perfect match to Bora’s long-term growth."

Taiwan-based CDMO Bora Pharmaceuticals is expanding its business in the United States, acquiring Minnesota generics manufacturer Upsher-Smith Laboratories for $210 million.

Upsher-Smith, which was established in 1919, brings two manufacturing facilities that are five miles apart in the suburbs of Minneapolis. These become Bora’s first facilities in the U.S.

Bora also has a 170,000 square meter plant in Mississauga, Ontario, which acts as its North America headquarters.

Upsher-Smith produces a portfolio of 48 generic products. Its plants can handle packaging and a range of formulations including oral solids, liquids and topical powders. The sites have a total annual capacity of 3.5 billion doses.

“This is a significant milestone for Bora Group, marking the most critical expansion of Bora’s presence in the U.S. market and significantly enhancing Bora’s position as a global competitor,” Bora CEO Bobby Sheng said in a release.

The acquisition also supports Bora's commercial prescription business, TWi, which it bought out in September of 2022, according to Bora's release.

This is the second sale of Upsher-Smith in seven years. In 2017, Sawai Pharmaceuticals of Japan gained the company to bolster its presence in the U.S.

Sawai now is selling off the subsidiary after the “business environment became increasingly complex” and recording “significant impairments of goodwill and other assets” in March of 2022.

Last year, Upsher-Smith closed its plant in Colorado and completed a $100 million expansion of its facility in Maple Grove, Minnesota.

Bora, which is the largest manufacturer of pharmaceuticals in Taiwan, has two plants in the country.

“The synergies realized through the integration of all the resources deployed by Bora will significantly accelerate its growth, propelling Bora to become a leading competitor in the pharma industry,” the company said in its release.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。